GeneReach Biotechnology Corp. Statistics
GeneReach Biotechnology Corp. (4171) Stock Statistics & Valuation Metrics
Total Valuation
GeneReach Biotechnology Corp. has a market cap or net worth of TWD 896.99M. The enterprise value is TWD 790.40M.
- Market Cap
- TWD 896.99M
- Enterprise Value
- TWD 790.40M
Share Statistics
GeneReach Biotechnology Corp. has 58,057,470 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 58,057,470
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
GeneReach Biotechnology Corp.’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -9.29%.
- Return on Equity (ROE)
- -0.19
- Return on Assets (ROA)
- -0.13
- Return on Invested Capital (ROIC)
- -9.29%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 1.94M
- Profits Per Employee
- -919.01K
- Employee Count
- 120
- Asset Turnover
- 0.26
- Inventory Turnover
- 2.21
Valuation Ratios
The current PE Ratio of GeneReach Biotechnology Corp. is -39.58. GeneReach Biotechnology Corp.’s PEG ratio is -0.19.
- PE Ratio
- -39.58
- PS Ratio
- 3.60
- PB Ratio
- 1.51
- Price to FCF
- 4563.56
- Price to Operating Cash Flow
- 71.61
- PEG Ratio
- -0.19
Income Statement
In the last 12 months, GeneReach Biotechnology Corp. had revenue of 232.74M and earned -110.28M in profits. Earnings per share was -1.93.
- Revenue
- 232.74M
- Gross Profit
- 160.93M
- Operating Income
- -79.86M
- Pretax Income
- -116.47M
- Net Income
- -110.28M
- EBITDA
- -8.77M
- Earnings Per Share (EPS)
- -1.93
Cash Flow
In the last 12 months, operating cash flow was 12.05M and capital expenditures -11.86M, giving a free cash flow of 190.00K billion.
- Operating Cash Flow
- 12.05M
- Free Cash Flow
- 190.00K
- Free Cash Flow per Share
- 0.00
Dividends & Yields
GeneReach Biotechnology Corp. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.02%
- Earnings Yield
- -4.74%
Stock Price Statistics
- Beta
- 0.70
- 52-Week Price Change
- -27.80%
- 50-Day Moving Average
- 16.84
- 200-Day Moving Average
- 18.08
- Relative Strength Index (RSI)
- 29.37
- Average Volume (3m)
- 155.88K
Important Dates
GeneReach Biotechnology Corp. upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
GeneReach Biotechnology Corp. as a current ratio of 2.41, with Debt / Equity ratio of 38.39%
- Current Ratio
- 2.41
- Quick Ratio
- 2.25
- Debt to Market Cap
- 0.13
- Net Debt to EBITDA
- -6.29
- Interest Coverage Ratio
- -12.28
Taxes
In the past 12 months, GeneReach Biotechnology Corp. has paid -3.54M in taxes.
- Income Tax
- -3.54M
- Effective Tax Rate
- 0.03
Enterprise Valuation
GeneReach Biotechnology Corp. EV to EBITDA ratio is 64.66, with an EV/FCF ratio of 4970.41.
- EV to Sales
- 3.97
- EV to EBITDA
- 64.66
- EV to Free Cash Flow
- 4970.41
- EV to Operating Cash Flow
- 78.37
Balance Sheet
GeneReach Biotechnology Corp. has TWD 395.82M in cash and marketable securities with TWD 220.26M in debt, giving a net cash position of TWD 175.56M billion.
- Cash & Marketable Securities
- TWD 395.82M
- Total Debt
- TWD 220.26M
- Net Cash
- TWD 175.56M
- Net Cash Per Share
- TWD 3.02
- Tangible Book Value Per Share
- TWD 9.53
Margins
Gross margin is 73.97%, with operating margin of -4.34%, and net profit margin of -9.67%.
- Gross Margin
- 73.97%
- Operating Margin
- -4.34%
- Pretax Margin
- -11.99%
- Net Profit Margin
- -9.67%
- EBITDA Margin
- 7.23%
- EBIT Margin
- -4.34%
Analyst Forecast
The average price target for GeneReach Biotechnology Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 11.99%
- EPS Growth Forecast
- 84.94%
